Do not submit same batch no. of cough syrup to two different laboratories: DCGI tells Manufacturers, Exporters

Published On 2023-08-08 12:30 GMT   |   Update On 2023-08-08 12:30 GMT
Advertisement

New Delhi: Safeguarding public health, through a recent notification, the Drug Controller General of India (DCGI) has notified all drug manufacturers' associations and exporters not to submit the same batch of cough syrup to more than one laboratory at a time, as this practice is highly objectionable and not acceptable from a regulatory standpoint.

This came when two different government laboratories accredited by the National Accreditation Board for Testing and Calibration (NABL) received cough syrup from the same manufacturer/exporter with the same batch number for testing purposes.

Advertisement

In regards to the above, the Drug Controller General of India (DCGI) highlighted, "It is noticed that cough syrup samples of the same batch number, manufactured by the same manufacturer (for export purposes), are being received by two different laboratories for testing purposes, which is highly objectionable and not acceptable."

Furthermore, the notification added,

"It is hereby directed that no manufacturer or exporter shall submit the same batch nos. of cough syrup manufactured by them to two or more laboratories."

In addition, the DCGI also specified,

"If such cases are reported further, the samples of those manufacturers or exporters shall not be accepted for testing by any of the NABL accredited government laboratories."

The DCGI directive ensures that the evaluation of the cough syrup's quality and safety is conducted in a standardized and reliable manner. By prohibiting manufacturers from submitting the same batch of cough syrup to multiple labs simultaneously, the DCGI is taking a proactive step towards maintaining the integrity of the testing process and safeguarding public health. Submitting the same batch of cough syrup to multiple labs at the same time raises concerns about potential variations in test results and the potential for conflicting interpretations. This practice not only undermines the credibility of the regulatory process but also presents a risk to patient safety.

Also Read:Zydus Lifesciences gets CDSCO panel nod to manufacture, market Relugolix Tablets

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News